Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II. J of Skin [Internet]. 2024 Mar. 18 [cited 2025 Apr. 18];8(2):s396. Available from: https://skin.dermsquared.com/skin/article/view/2671